- Home
- SOC vs NVCR Comparison
SOC vs NVCR Comparison
Compare SOC & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOC
- NVCR
- Stock Information
- Founded
- SOC 2020
- NVCR 2000
- Country
- SOC United States
- NVCR Switzerland
- Employees
- SOC N/A
- NVCR N/A
- Industry
- SOC
- NVCR Medical/Dental Instruments
- Sector
- SOC
- NVCR Health Care
- Exchange
- SOC Nasdaq
- NVCR Nasdaq
- Market Cap
- SOC 2.2B
- NVCR 2.3B
- IPO Year
- SOC N/A
- NVCR 2015
- Fundamental
- Price
- SOC $25.92
- NVCR $18.86
- Analyst Decision
- SOC Buy
- NVCR Strong Buy
- Analyst Count
- SOC 4
- NVCR 4
- Target Price
- SOC $26.25
- NVCR $37.50
- AVG Volume (30 Days)
- SOC 1.3M
- NVCR 840.4K
- Earning Date
- SOC 05-14-2025
- NVCR 05-01-2025
- Dividend Yield
- SOC N/A
- NVCR N/A
- EPS Growth
- SOC N/A
- NVCR N/A
- EPS
- SOC N/A
- NVCR N/A
- Revenue
- SOC N/A
- NVCR $605,220,000.00
- Revenue This Year
- SOC N/A
- NVCR $3.41
- Revenue Next Year
- SOC N/A
- NVCR $9.24
- P/E Ratio
- SOC N/A
- NVCR N/A
- Revenue Growth
- SOC N/A
- NVCR 18.82
- 52 Week Low
- SOC $10.11
- NVCR $11.70
- 52 Week High
- SOC $32.33
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- SOC 51.35
- NVCR 39.74
- Support Level
- SOC $24.20
- NVCR $18.23
- Resistance Level
- SOC $27.06
- NVCR $19.06
- Average True Range (ATR)
- SOC 1.28
- NVCR 0.83
- MACD
- SOC 0.16
- NVCR 0.08
- Stochastic Oscillator
- SOC 75.90
- NVCR 18.98
About SOC Sable Offshore Corp. Common Stock
Sable Offshore Corp is a Houston-based independent upstream company focused on responsibly developing the prolific Santa Ynez Unit in federal waters offshore California.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.